Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) has announced the results of its Phase 1b study of PTX-100 in patients with advanced malignancies. …
Prescient announces the results of PTX-100 Phase 1b study in T-cell lymphoma patients
December 11, 2023 Australian Biotech
Latest Video
New Stories
-
Specialised Therapeutics expands partnership with Incyte to include two additional therapies
June 13, 2025 - - Latest News -
New immunisation strategy highlights COVID impact, priority patients and new technologies
June 12, 2025 - - Latest News -
Medicines Australia establishes radiopharmaceuticals working group
June 12, 2025 - - Latest News -
MSD Australia and New Zealand certified a 'Great Place to Work'
June 12, 2025 - - Latest News -
Specialised Therapeutics expands partnership with Incyte to include two additional therapies
June 12, 2025 - - Latest News -
Novo Nordisk partners with Heart of Australia to expand clinical trial access
June 12, 2025 - - Latest News -
Mark Butler starts the process of NDIS pricing reform
June 11, 2025 - - Latest News